Working… Menu

BIBF 1120 in Recurrent Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01251484
Recruitment Status : Completed
First Posted : December 2, 2010
Last Update Posted : October 4, 2012
Boehringer Ingelheim
University of Copenhagen
Information provided by (Responsible Party):
Ulrik Lassen, Rigshospitalet, Denmark

Tracking Information
First Submitted Date  ICMJE December 1, 2010
First Posted Date  ICMJE December 2, 2010
Last Update Posted Date October 4, 2012
Study Start Date  ICMJE January 2011
Actual Primary Completion Date August 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 1, 2010)
Response rate [ Time Frame: Response evaluation every 8 weeks ]
MacDonald criteria
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 1, 2010)
Adverse events [ Time Frame: Assessed every 2 weeks ]
CTCAE version 4.0
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE BIBF 1120 in Recurrent Glioblastoma Multiforme
Official Title  ICMJE Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme
Brief Summary

VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.

VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Recurrent Glioblastoma
Intervention  ICMJE Drug: BIBF1120
Tablet 200 mg twice daily until progression
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 3, 2012)
Original Estimated Enrollment  ICMJE
 (submitted: December 1, 2010)
Actual Study Completion Date  ICMJE August 2012
Actual Primary Completion Date August 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria

  • Written informed consent
  • Histological verification of primary GBM and failure after radiotherapy and TMZ

    - Previously received radiotherapy and TMZ

  • More than 4 weeks since any of the following prior treatments

    • Chemotherapy (6 weeks for nitrosureas or mitomycin C)
    • Radiotherapy to nontarget lesions or lesions that are not to be biopsied
    • Investigational agents
  • More than 6 months since prior major surgery or open biopsy and recovered (only 6 weeks required if operation is for recurrent BGM)
  • ● ECOG performance status 0-1
  • Age > 18 years
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • Fertile females must use anticonception (p- pills, IUD, depot injection of gestagen, subdermal
  • implantation, hormonal vaginal ring or transdermal depot plaster, throughout the study and 3
  • months after discontinuation of study drugs. Fertile men must use dobbelt barrier method
  • (preservative with sperm inhibiting creme) or female partner uses the above mentioned
  • contraception.
  • Fertile males must use preservatives.

Exclusions criteria

  • Prior treatment with BIBF 1120 or any other VEGFR inhibitor, except bevacizumab in Group 2
  • Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug.
  • Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
  • Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial
  • Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid<325mg per day
  • Major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
  • History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
  • Known inherited predisposition to bleeding or thrombosis
  • Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion)
  • Proteinuria CTCAE grade 2 or greater
  • Hepatic function: total bilirubin outside of normal limits; ALT or AST > 1.5 ULN
  • Coagulation parameters: International normalised ratio ( INR) > 2, prothrombin time

    - (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN

  • Absolute neutrophil count ( ANC) < 1500/ml, platelets < 100000/ml, Haemoglobin < 9.0 g/dl
  • Other malignancies within the past 5 years other then basal cell skin cancer or carcinoma in situ of the cervix
  • Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
  • Active or chronic hepatitis C and/or B infection
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
  • Pregnancy or breast feeding
  • Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • active alcohol or drug abuse
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Denmark
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01251484
Other Study ID Numbers  ICMJE BIBF1120 GBM
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ulrik Lassen, Rigshospitalet, Denmark
Study Sponsor  ICMJE Ulrik Lassen
Collaborators  ICMJE
  • Boehringer Ingelheim
  • University of Copenhagen
Investigators  ICMJE Not Provided
PRS Account Rigshospitalet, Denmark
Verification Date October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP